- Home
- ENGS vs RNXT Comparison
ENGS vs RNXT Comparison
Compare ENGS & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGS
- RNXT
- Stock Information
- Founded
- ENGS 1998
- RNXT 2012
- Country
- ENGS United Kingdom
- RNXT United States
- Employees
- ENGS N/A
- RNXT N/A
- Industry
- ENGS
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- ENGS
- RNXT Health Care
- Exchange
- ENGS NYSE
- RNXT Nasdaq
- Market Cap
- ENGS 45.6M
- RNXT 44.6M
- IPO Year
- ENGS 2025
- RNXT 2021
- Fundamental
- Price
- ENGS $1.67
- RNXT $1.36
- Analyst Decision
- ENGS
- RNXT Strong Buy
- Analyst Count
- ENGS 0
- RNXT 2
- Target Price
- ENGS N/A
- RNXT $7.25
- AVG Volume (30 Days)
- ENGS 620.5K
- RNXT 190.7K
- Earning Date
- ENGS 01-01-0001
- RNXT 08-12-2025
- Dividend Yield
- ENGS N/A
- RNXT N/A
- EPS Growth
- ENGS N/A
- RNXT N/A
- EPS
- ENGS N/A
- RNXT N/A
- Revenue
- ENGS $12,134,254.00
- RNXT $240,000.00
- Revenue This Year
- ENGS N/A
- RNXT $3,186.05
- Revenue Next Year
- ENGS N/A
- RNXT $291.93
- P/E Ratio
- ENGS N/A
- RNXT N/A
- Revenue Growth
- ENGS 59.88
- RNXT N/A
- 52 Week Low
- ENGS $1.36
- RNXT $0.75
- 52 Week High
- ENGS $10.24
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- ENGS N/A
- RNXT 58.97
- Support Level
- ENGS N/A
- RNXT $1.26
- Resistance Level
- ENGS N/A
- RNXT $1.40
- Average True Range (ATR)
- ENGS 0.00
- RNXT 0.05
- MACD
- ENGS 0.00
- RNXT -0.01
- Stochastic Oscillator
- ENGS 0.00
- RNXT 48.70
About ENGS ENERGYS GROUP LTD
Energys Group Ltd provides end-to-end customized solutions and services involving the retrofitting of existing infrastructure to reduce their CO2 emissions. The Company's customers include large national account end-users, including universities, schools, hospitals and electrical distributors in the United Kingdom.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.